Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.01), Briefing.com reports. During the same period in the prior year, the business earned ($0.29) earnings per share.

In other Aevi Genomic Medicine news, Director Sol J. Barer bought 421,032 shares of Aevi Genomic Medicine stock in a transaction dated Tuesday, October 17th. The stock was bought at an average price of $1.26 per share, for a total transaction of $530,500.32. Following the completion of the acquisition, the director now directly owns 1,028,032 shares of the company’s stock, valued at $1,295,320.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael F. Cola bought 119,047 shares of Aevi Genomic Medicine stock in a transaction dated Tuesday, October 17th. The stock was acquired at an average price of $1.26 per share, with a total value of $149,999.22. Following the acquisition, the chief executive officer now directly owns 218,483 shares of the company’s stock, valued at $275,288.58. The disclosure for this purchase can be found here. Insiders bought 645,910 shares of company stock valued at $811,792 in the last 90 days. Corporate insiders own 15.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Aevi Genomic Medicine, Inc. (GNMX) Posts Earnings Results, Misses Estimates By $0.01 EPS” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/02/aevi-genomic-medicine-inc-gnmx-posts-earnings-results-misses-estimates-by-0-01-eps.html.

A number of equities analysts have recently weighed in on GNMX shares. Needham & Company LLC cut their price target on Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, August 16th. Jefferies Group LLC reissued a “hold” rating and issued a $1.50 price target on shares of Aevi Genomic Medicine in a report on Thursday, September 28th.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.